ANGEL CHANG

• Responsible for CGMH-LK, FEMH, CGH, FJCUH for Taxotere, Targocid, Depakine, and Sarclisa
• Mainly engaged in ONC, GS, GU, ID and Hema
• 2021 Top performer award-Gold card
• Taxotere sales:growth rate is 24% compared to 2021
• 2020 growth rate is 15% compared to 2019
• 2019 growth rate is compared to 2018
• Build up the communication channel between ONC and GU in FEMH, transform the GU from non-chemodepartment to a department willing to prescribe Taxotere in prostate cancer patients
• Demonstrated the positive thinking to face the critical challenge (PAH-LT& 聖母&CGH defense generic)
• Preparation of the best option for annual bargaining in FEMH
• Utilized OCE and strategies to promote consistent and effective sales pitches
• Assisted Product Managers with brainstorming and reviewing proposals appropriately
• (Christmas Program)
• Managed leads and followed up new business opportunities to close deals with prospects.

• Responsible for SKH, CGH, TAH, TPECH for PPI and Hepatitis B, C
• Mainly engaged in GI, GS, NS and ER
• The average achievement rate is 100% and achieve annual sales target according to Priority
• Took the lead in negotiating the prices on the newly invented medicine with the hospitals' purchasedrepresentatives and successfully had it introduced in the hospitals by Nov, 2017
• Business Bridge between Company and responsible Customer
• Coordinate efforts with territory partners in a team environment
• To take responsibility for Customer promotion activities.

• Responsible for NTUH, VGH for antibiotic
• Mainly engaged in CHEST, ER, GI, ID and ONCOLOGY
• The average achievement rate is 100% and achieved annual sales target according to Priority.

Luteolin inhibits invasion of breast, multiple signal pathways